Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial
- Lieverse, R.I.Y. (Relinde I Y)
- Van Limbergen, E.J. (Evert J.)
- Oberije, C. (Cary)
- Troost, E.G.C. (Esther G C)
- Hadrup, S.R. (Sine R.)
- Dingemans, A.-M.C. (Anne-Marie C)
- Hendriks, L.E.L. (Lizza E L)
- Eckert, F. (Franziska)
- Hiley, C. (Crispin)
- Dooms, C. (Christophe)
- Lievens, Y. (Yolande)
- de Jong, M.C. (Monique C.)
- Bussink, J. (Johan)
- Geets, X. (Xavier)
- Valentini, V. (Vincenzo)
- Elia, G. (Giuliano)
- Neri, D. (Dario)
- Billiet, C. (Charlotte)
- Abdollahi, A. (Amir)
- Pasquier, D. (David)
- Boisselier, P. (Pierre)
- Yaromina, A. (Ala)
- Ruysscher, D.K.M. (Dirk) de
- Dubois, L.
- Lambin, P. (Philippe)
DOIAbstract
BACKGROUND: About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint inhibitors (ICI), either alone or in combination with chemotherapy, have become standard of care (SOC) for most good performance status patients. However, most patients will not obtain long-term benefit and new treatment strategies are therefore needed. We previously demonstrated clinical safety of the tumour-selective immunocytokine L19-IL2, consisting of the anti-ED-B scFv L19 antibody coupled to IL2, combined with stereotactic ablative radiotherapy (SABR). METHODS: This investigator-initiated, multicentric, randomised co...
Add to ORKG